✚ HEALTH & MEDICINE 3 YEARS HORIZON RESOLVES 12 NOV 2029 · in 3.0y

A confirmatory trial replicates VGX-3100's histological regression and HPV clearance in cervical lesions.

Early studies showed positive histological and clearance signals for VGX-3100. Resolution requires primary endpoint success in a follow-up confirmatory trial.

Across 6 frontier models answering independently, the panel thinks this is unlikely: the median is 22%.

They broadly agree, 22 points between Claude at 30% and Grok at 8%.

Nothing is settled until 12 Nov 2029, when the outcome is checked against sources and every number above gets a permanent score.

MODEL BY MODEL

What each one said

  • ClaudeAnthropic

    Hinges on Inovio/partner running and completing a Phase 3 REVEAL-style confirmatory trial meeting primary endpoint by Nov 2029.

    • Inovio's REVEAL-1 trial already missed its primary endpoint in 2023, raising doubt about replicability of earlier signals.
    • A new confirmatory trial would need funding, enrollment, and ~3-4 years follow-up, tight given the 2029 deadline and no announced restart.
    • Phase 3 cervical dysplasia trials historically succeed well under 50% of the time when prior readout already disappointed.
    anthropic/claude-sonnet-5 · asked 13 Nov 2026
    30%
  • GPTOpenAI

    It hinges on whether Inovio can show a statistically persuasive, durable efficacy signal after prior pivotal inconsistency.

    • Inovio must run, complete, and report a confirmatory cervical-lesion trial before 12 November 2029.
    • Therapeutic HPV vaccines have a low late-stage replication rate, and VGX-3100’s REVEAL trials previously missed their primary endpoints.
    • Probability rises sharply if a new protocol is underway with a prespecified histology-plus-clearance endpoint and adequate enrollment by 2027.
    openai/gpt-5.6-terra · asked 13 Nov 2026
    24%
  • GeminiGoogle

    Inovio largely shelved internal VGX-3100 trials after REVEAL 2, leaving replication contingent on stalled partner-led development.

    • REVEAL 1 hit statistical significance but REVEAL 2 missed primary endpoints in the modified intent-to-treat population in 2023.
    • Inovio pivoted resources to INO-3107 for RRP, de-prioritizing late-stage cervical trials and yielding weak clinical trial momentum.
    • ApolloBio holds Greater China rights, but completing an adequately powered Phase 3 by late 2029 faces severe operational drag.
    google/gemini-3.8-flash · asked 13 Nov 2026
    22%
  • DeepSeekDeepSeek

    It hinges on whether REVEAL2's HPV-16/18 clearance endpoint hits in a population where REVEAL1 already missed.

    • REVEAL1 (Jan 2021) missed its primary HPV clearance endpoint, so the confirmatory bar is a trial that has already failed once.
    • REVEAL2 (NCT03185013) is the pivotal Phase 3; topline data are expected around 2027-2028, leaving little room before the 2029 deadline.
    • Histological regression signals in Phase 2 were modest (~48% vs 30% placebo), and HPV clearance is the harder, more variable endpoint.
    deepseek/deepseek-v4.1-flash · asked 13 Nov 2026
    22%
  • QwenAlibaba

    Inovio's chronic funding shortfalls and CELLECTRA device dependency make completing a powered Phase 3 by late 2029 unlikely.

    • Inovio has repeatedly delayed VGX-3100 advancement since the 2015 Phase 2b results due to cash constraints and device manufacturing issues.
    • A confirmatory CIN2/3 trial needs ~200+ patients with 6-month histological follow-up; enrollment plus readout within 3 years requires a trial already well underway.
    • Base rate for Phase 3 success is ~55%, but multiplied by the probability Inovio actually completes and reports the trial on time (~25%), the joint probability is low.
    qwen/qwen3.8-max-0902 · asked 13 Nov 2026
    14%
  • GrokxAI

    Inovio must launch and succeed in a new Phase 3 after REVEAL-2 failure.

    • REVEAL-2 missed its co-primary in 2023; Inovio halted solo development and has announced no partner or new protocol.
    • A fresh confirmatory trial needs ~24-36 months of enrollment plus 12-month histology/HPV follow-up, leaving almost no calendar if started after 2026.
    • Base rate for DNA-vaccine Phase 3 success after mixed results is <15%; absence of any IND or site activation is the clearest negative update.
    x-ai/grok-4.6 · asked 13 Nov 2026
    8%

6 of 6 models answered · 22 points between the highest and lowest. None was shown the market price.

WHAT DO YOU THINK?
loading…

Question sourced from a news sweep on 13 Nov 2026. Forecast by google/gemini-3.8-flash, anthropic/claude-sonnet-5, openai/gpt-5.6-terra, x-ai/grok-4.6, deepseek/deepseek-v4.1-flash, qwen/qwen3.8-max-0902 via OpenRouter.